SCHEMBL2324993

SCHEMBL2324993

CN(C)c1ccc(-c2ccc(C=O)o2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
KDM4E B2RXH2 5/20 0.61
LMNA P02545 2/20 0.61
TDP1 Q9NUW8 2/20 0.56
GAA P10253 1/20 0.52
MAPT P10636 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HSP90AA1 P07900 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
STAT1 P42224 1/20 0.48
CYP2A6 P11509 1/20 0.47
CYP2A13 Q16696 1/20 0.47
CYP2E1 P05181 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2B6 P20813 1/20 0.46
CYP2C19 P33261 1/20 0.46
LDHA P00338 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396870 0.84 ALDH1A1 (0.80) ALDH1A1KDM4ELMNATDP1GAA
SCHEMBL28757733 0.81 KDM4E (0.56) ALDH1A1KDM4ELMNATDP1GAA
SCHEMBL3033218 0.80 ALDH1A1 (0.56) ALDH1A1KDM4ELMNATDP1GAA
SCHEMBL24089762 0.80 ALDH1A1 (0.50) ALDH1A1KDM4ELMNATDP1GAA
SCHEMBL2318474 0.79 KDM4E (0.67) ALDH1A1KDM4ELMNATDP1GAA
SCHEMBL13043078 0.79 KDM4E (0.57) ALDH1A1KDM4ELMNATDP1MAPT
SCHEMBL11778011 0.78 SMN1; SMN2 (0.63) ALDH1A1KDM4ETDP1GAAMAPT
SCHEMBL11778016 0.78 SMN1; SMN2 (0.63) ALDH1A1KDM4ETDP1GAAMAPT
SCHEMBL10092801 0.78 ALDH1A1 (0.65) ALDH1A1KDM4ELMNATDP1GAA
SCHEMBL12177745 0.77 ALDH1A1 (0.69) ALDH1A1KDM4ELMNATDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338465-B2 Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis CORNELL RESEARCH FOUNDATION, INC. (US) 2012-12-25 US disclosed
WO-2011094890-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2011-08-11 WO disclosed
US-20100210577-A1 CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS CORNELL RESEARCH FOUNDATION, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210577-A1 CYCLIC CARBOXYLIC ACID RHODANINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS RARG, SDHA, RARS2 ALDH1A1 270/4885KDM4E 4138/4885LMNA 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.